Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase

Biochemical and Biophysical Research Communications

Volumn 290, Issue 2, 2002, Pages 869-873

  Thompson, Keith ^a   Dunford, James E ^a   Rogers, Michael J ^a   Ebetino, Frank H ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Bisphosphonate; Farnesyl diphosphate synthase; Isopentenyl diphosphate isomerase; Mevalonate; Osteoclast; Prenylation

Indexed keywords

2 AMINOPHENYL 2 ETHANE 1 HYDROXY 1,1 BISPHOSPHONIC ACID; 4 AMINOPHENYL 2 ETHANE 1,1 BISPHOSPHONIC ACID; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GERANYLTRANSFERASE; ISOMERASE INHIBITOR; ISOPENTENYL DIPHOSPHATE DELTA ISOMERASE; MEVALONIC ACID; NE 10571; NE 21650; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; IC 50; MACROPHAGE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRENYLATION; PRIORITY JOURNAL;

EID: 0036290920     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2001.6289     Document Type: Article

References (20)

1. Clinical disorders of bone resorption
2. Treatment of osteoporosis with bisphosphonates
3. Cellular and molecular mechanisms of action of bisphosphonates
4. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
5. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro
6. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates
7. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
8. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
9. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase
10. Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298
11. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro
12. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
13. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
14. Human isopentenyl diphosphate:dimethylallyl diphosphate isomerase: Overproduction, purification, and characterization
15. Isopentenyldiphosphate delta-isomerase
16. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation
17. The molecular mechanism of action of the anti-resorptive and anti-inflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis
18. Induction of osteoclast characteristics in cultured avian blood monocytes: Modulation by osteoblasts and 1, 25-(OH)2 vitamin D3
19. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis
20. 1-Hydroxy-3-(methylpentylamino)-propylidene-1, 1-bisphosphonic acid as a potent inhibitor of squalene synthase